CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities
4 affiliations
- 1School of Biomedical Engineering University of New South Wales Sydney Australia
- 2Australian Centre for NanoMedicine University of New South Wales Sydney Australia
- 3The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Department of Emergency, The Second Affiliated Hospital Guangzhou Medical University Guangzhou People's Republic of China
- 4Chongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Chongqing University Cancer Hospital Chongqing University Chongqing People's Republic of China
Abstract
DNA and RNA methylation are key epigenetic and epitranscriptomic modifications involved in gene regulation, genome stability, RNA metabolism, and disease progression. Aberrant methylation patterns in cell‐free DNA and RNA have emerged as valuable biomarkers for cancer detection, disease monitoring, and therapeutic stratification. However, conventional methods such as bisulfite sequencing, methylation‐specific PCR, MeRIP‐seq, SCARLET, and LC–MS/MS often require harsh processing, high sample input, complex instrumentation, or lack site‐specific resolution, limiting their clinical and point‐of‐care applications. CRISPR‐based diagnostics provide a promising alternative by combining programmable nucleic acid recognition with collateral cleavage‐mediated signal amplification. This review summarizes recent CRISPR strategies for detecting DNA and RNA methylation, including chemical conversion‐assisted assays, restriction enzyme‐mediated detection, direct amplification‐free sensing based on methylation‐modulated Cas activity, detection of oxidized cytosine derivatives, reverse transcription‐mediated Cas12 detection of m6A, and structure‐sensitive Cas13 sensing. We highlight how methylation‐dependent sequence conversion, enzyme accessibility, polymerase behavior, and nucleic acid structure can be translated into CRISPR‐readable signals. Finally, we discuss current translational challenges and emerging opportunities in point‐of‐care methylation diagnostics, integrated DNA–RNA profiling, engineered Cas effectors, AI‐guided assay design, and CRISPR‐compatible methylome analysis.
Related
- DNA/RNA Methylation-Driven Coronary Microvascular Dysfunction: Emerging Pathogenic Mechanisms and Therapeutic Opportunities for Heart Failure in Diabetes
- Metabolic rewiring at the obesity-estrogen-polyamine axis in endometrial cancer: emerging mechanisms and translational opportunities.
- Methylation-sensitive restriction endonuclease-based amplification assay for detecting DNA methylation in colorectal cancer: a cross-sectional study.
- HPV E6/E7, O-GlcNAcylation and mitochondrial remodeling in cervical cancer: mechanistic links and translational opportunities
- Proteomic Landscapes of Aging and Disease: Multi-Omics Integration, Machine Learning, and Translational Opportunities
BibTeX
@article{chen2026crispr,
title = {{CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities}},
author = {Kaixin Chen and Biyao Yang and Rui Sang and Wenjie Chen and Tingxiu Xiang and Fei Deng},
journal = {Bioengineering \& Translational Medicine},
year = {2026},
month = aug,
doi = {10.1002/btm2.70174},
url = {https://doi.org/10.1002/btm2.70174},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - CRISPR technologies for detecting DNA and RNA methylation: Mechanisms, platforms, and translational opportunities
AU - Kaixin Chen
AU - Biyao Yang
AU - Rui Sang
AU - Wenjie Chen
AU - Tingxiu Xiang
AU - Fei Deng
PY - 2026
DA - 2026/08/19
JO - Bioengineering & Translational Medicine
DO - 10.1002/btm2.70174
UR - https://doi.org/10.1002/btm2.70174
AB - DNA and RNA methylation are key epigenetic and epitranscriptomic modifications involved in gene regulation, genome stability, RNA metabolism, and disease progression. Aberrant methylation patterns in cell‐free DNA and RNA have emerged as valuable biomarkers for cancer detection, disease monitoring, and therapeutic stratification. However, conventional methods such as bisulfite sequencing, methylation‐specific PCR, MeRIP‐seq, SCARLET, and LC–MS/MS often require harsh processing, high sample input, complex instrumentation, or lack site‐specific resolution, limiting their clinical and point‐of‐care applications. CRISPR‐based diagnostics provide a promising alternative by combining programmable nucleic acid recognition with collateral cleavage‐mediated signal amplification. This review summarizes recent CRISPR strategies for detecting DNA and RNA methylation, including chemical conversion‐assisted assays, restriction enzyme‐mediated detection, direct amplification‐free sensing based on methylation‐modulated Cas activity, detection of oxidized cytosine derivatives, reverse transcription‐mediated Cas12 detection of m6A, and structure‐sensitive Cas13 sensing. We highlight how methylation‐dependent sequence conversion, enzyme accessibility, polymerase behavior, and nucleic acid structure can be translated into CRISPR‐readable signals. Finally, we discuss current translational challenges and emerging opportunities in point‐of‐care methylation diagnostics, integrated DNA–RNA profiling, engineered Cas effectors, AI‐guided assay design, and CRISPR‐compatible methylome analysis.
SN - 2380-6761
ER -